{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-08T19:00:30.581018+00:00","company":{"ticker":"FENC","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC."},"pagination":{"limit":100,"returned":16,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Petrichor Opportunities Fund I LP","detail":"credit_facility","count":2,"first_seen":"2023-12-06T23:59:59+00:00","last_seen":"2023-12-06T23:59:59+00:00","evidence_fact_ids":[89827,89828]},{"display_name":"Norgine Pharma UK Limited","detail":"license","count":1,"first_seen":"2024-03-21T23:59:59+00:00","last_seen":"2024-03-21T23:59:59+00:00","evidence_fact_ids":[65556]}],"lender":[{"display_name":"Petrichor Opportunities Fund I LP","detail":"convertible_notes","count":1,"first_seen":"2023-12-06T23:59:59+00:00","last_seen":"2023-12-06T23:59:59+00:00","evidence_fact_ids":[89830]}]},"facts":[{"fact_type":"executive_change","fact_key":"6b3df1ef45","cik":1211583,"ticker":"FENC","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2026-04-28T23:59:59+00:00","payload":{"action":"retire","action_category":"departure","departure_tone":"retirement","effective_date":null,"interim":false,"role":"Board member","role_category":"director","successor_name":null,"successor_named":false},"claim":"Rostislav Raykov departed as Board member at FENNEC PHARMACEUTICALS INC..","evidence_excerpt":"On April 27, 2026, Rostislav Raykov notified Fennec Pharmaceuticals Inc. (the \"Company\") of his desire to retire from the Company's Board of Directors (the \"Board\") and that he will not stand for re-election at the Company's 2026 annual meeting of shareholders (the \"Annual Meeting\").","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-26-050433","anchor_url":"https://secwatch.observer/filing/0001104659-26-050433#claim-6b3df1ef45","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465926050433/0001104659-26-050433-index.htm"},{"fact_type":"executive_change","fact_key":"1b2d559657","cik":1211583,"ticker":"FENC","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2024-10-30T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-28","interim":false,"role":"Chief Strategy Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Christiana Cioffi was appointed as Chief Strategy Officer at FENNEC PHARMACEUTICALS INC..","evidence_excerpt":"Ms. Christiana Cioffi, MBA, as Chief Strategy Officer (\"CSO\"),","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-112405","anchor_url":"https://secwatch.observer/filing/0001104659-24-112405#claim-1b2d559657","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924112405/0001104659-24-112405-index.htm"},{"fact_type":"executive_change","fact_key":"be1b5e267c","cik":1211583,"ticker":"FENC","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2024-10-30T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-28","interim":false,"role":"Chief Commercial Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Terry Evans was appointed as Chief Commercial Officer at FENNEC PHARMACEUTICALS INC..","evidence_excerpt":"Mr. Terry Evans as Chief Commercial Officer (\"CCO\"),","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-112405","anchor_url":"https://secwatch.observer/filing/0001104659-24-112405#claim-be1b5e267c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924112405/0001104659-24-112405-index.htm"},{"fact_type":"executive_change","fact_key":"38efaa76bf","cik":1211583,"ticker":"FENC","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2024-10-30T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-28","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Pierre S. Sayad was appointed as Chief Medical Officer at FENNEC PHARMACEUTICALS INC..","evidence_excerpt":"On October 28, 2024, Fennec Pharmaceuticals Inc.'s (the \"Company\") announced the appointments of Mr. Pierre S. Sayad, PhD, M.S., as Chief Medical Officer (\"CMO\"),","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-112405","anchor_url":"https://secwatch.observer/filing/0001104659-24-112405#claim-38efaa76bf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924112405/0001104659-24-112405-index.htm"},{"fact_type":"executive_change","fact_key":"f5bfdf659d","cik":1211583,"ticker":"FENC","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2024-08-07T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-08-05","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Jeffrey S. Hackman was appointed as Director at FENNEC PHARMACEUTICALS INC..","evidence_excerpt":"the Company announced the appointment of Jeffrey S. Hackman as CEO and a member of the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-086369","anchor_url":"https://secwatch.observer/filing/0001104659-24-086369#claim-f5bfdf659d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924086369/0001104659-24-086369-index.htm"},{"fact_type":"executive_change","fact_key":"9f5bd062f4","cik":1211583,"ticker":"FENC","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2024-08-07T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-08-05","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Jeffrey S. Hackman was appointed as Chief Executive Officer at FENNEC PHARMACEUTICALS INC..","evidence_excerpt":"the Company announced the appointment of Jeffrey S. Hackman as CEO and a member of the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-086369","anchor_url":"https://secwatch.observer/filing/0001104659-24-086369#claim-9f5bd062f4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924086369/0001104659-24-086369-index.htm"},{"fact_type":"executive_change","fact_key":"337fd237b6","cik":1211583,"ticker":"FENC","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2024-08-07T23:59:59+00:00","payload":{"action":"depart","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":"Jeffrey S. Hackman","successor_named":true},"claim":"Rostislav Raykov departed as Chief Executive Officer at FENNEC PHARMACEUTICALS INC..","evidence_excerpt":"the Company announced the departure of Rostislav Raykov from his position as the Company’s Chief Executive Officer","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-086369","anchor_url":"https://secwatch.observer/filing/0001104659-24-086369#claim-337fd237b6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924086369/0001104659-24-086369-index.htm"},{"fact_type":"executive_change","fact_key":"8513616bf3","cik":1211583,"ticker":"FENC","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2024-07-02T23:59:59+00:00","payload":{"action":"departed","action_category":"departure","departure_tone":"not_disclosed","effective_date":"2024-06-30","interim":false,"role":"Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Adrian Haigh departed as Chief Operating Officer at FENNEC PHARMACEUTICALS INC..","evidence_excerpt":"On June 30, 2024, Adrian Haigh departed from his position as Fennec Pharmaceuticals Inc.’s (the \"Company\") Chief Operating Officer","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001104659-24-076936","anchor_url":"https://secwatch.observer/filing/0001104659-24-076936#claim-8513616bf3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924076936/0001104659-24-076936-index.htm"},{"fact_type":"earnings_release","fact_key":"3845b99f81297f73ddb266f8fe4d45f718ebc46b","cik":1211583,"ticker":"FENC","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2024-03-25T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"full year and fourth quarter 2023","report_date":"2024-03-21","result_type":"reported_results","revenue_text":null},"claim":"FENNEC PHARMACEUTICALS INC. reported financial results for full year and fourth quarter 2023.","evidence_excerpt":"Fennec Pharmaceuticals Inc. issued a news release announcing full year and fourth quarter financial results for the period ended December 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-038444","anchor_url":"https://secwatch.observer/filing/0001104659-24-038444#claim-3845b99f81297f73ddb266f8fe4d45f718ebc46b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924038444/0001104659-24-038444-index.htm"},{"fact_type":"material_agreement","fact_key":"b0abdb9352456a6e93bac07f4b9bb820ea6f7ccb","cik":1211583,"ticker":"FENC","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2024-03-21T23:59:59+00:00","payload":{"action":"entry","agreement_name":"License and Supply Agreement","agreement_type":"license","counterparty":"Norgine Pharma UK Limited","effective_date":"2024-03-15","item_codes_triggered":["1.01"],"value_text":"€40 million"},"claim":"FENNEC PHARMACEUTICALS INC. entered into License and Supply Agreement with Norgine Pharma UK Limited valued at €40 million (effective 2024-03-15).","evidence_excerpt":"On March 15, 2024, Fennec Pharmaceuticals, Inc., a Delaware corporation (“Fennec”) and wholly owned subsidiary of Fennec Pharmaceuticals Inc. (the “Company”), entered into a License and Supply Agreement (the “Agreement”) with Norgine Pharma UK Limited (“Norgine”)","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001104659-24-037255","anchor_url":"https://secwatch.observer/filing/0001104659-24-037255#claim-b0abdb9352456a6e93bac07f4b9bb820ea6f7ccb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924037255/0001104659-24-037255-index.htm"},{"fact_type":"earnings_release","fact_key":"a0ea98e5768b77792de4215c05793cbf736f40ec","cik":1211583,"ticker":"FENC","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2024-03-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"Full-year 2023","report_date":"2024-02-29","result_type":"preliminary_results","revenue_text":"approximately $20.7 to $21.2 million"},"claim":"FENNEC PHARMACEUTICALS INC. reported Full-year 2023 results: revenue approximately $20.7 to $21.2 million.","evidence_excerpt":"• Full-year 2023 net revenues are expected to be approximately $20.7 to $21.2 million.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-031470","anchor_url":"https://secwatch.observer/filing/0001104659-24-031470#claim-a0ea98e5768b77792de4215c05793cbf736f40ec","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924031470/0001104659-24-031470-index.htm"},{"fact_type":"earnings_release","fact_key":"10f2b04582b260813524dff80cb6d9e646c79e70","cik":1211583,"ticker":"FENC","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2024-03-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"Fourth quarter 2023","report_date":"2024-02-29","result_type":"preliminary_results","revenue_text":"approximately $9.2 to $9.7 million"},"claim":"FENNEC PHARMACEUTICALS INC. reported Fourth quarter 2023 results: revenue approximately $9.2 to $9.7 million.","evidence_excerpt":"• Fourth quarter 2023 net revenues are expected to be approximately $9.2 to $9.7 million, which represents approximately a 41-49% increase over the third quarter of 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-031470","anchor_url":"https://secwatch.observer/filing/0001104659-24-031470#claim-10f2b04582b260813524dff80cb6d9e646c79e70","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924031470/0001104659-24-031470-index.htm"},{"fact_type":"debt_financing","fact_key":"82dfa658fdd6f172cc760d06b2d4e3d595b3db54","cik":1211583,"ticker":"FENC","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2023-12-06T23:59:59+00:00","payload":{"counterparty":"Petrichor Opportunities Fund I LP","effective_date":"2023-12-04","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"greater of (a) US Prime Rate or (b) three and one-half percent (3.5%), plus the","item_codes_triggered":["2.03"],"maturity_text":"August 19, 2027","principal_text":"$5,000,000"},"claim":"FENNEC PHARMACEUTICALS INC. incurred convertible notes of $5,000,000 with Petrichor Opportunities Fund I LP at greater of (a) US Prime Rate or (b) three and one-half percent (3.5%), plus the maturing August 19, 2027.","evidence_excerpt":"On December 4, 2023, the Company closed a third tranche under the SPA in the amount of $5,000,000 and issued the Investor a Note in the same amount (the “Third Closing Note”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-123728","anchor_url":"https://secwatch.observer/filing/0001104659-23-123728#claim-82dfa658fdd6f172cc760d06b2d4e3d595b3db54","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465923123728/0001104659-23-123728-index.htm"},{"fact_type":"material_agreement","fact_key":"dfb76f9bba09c1492ac62e623f0f336e796e022c","cik":1211583,"ticker":"FENC","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2023-12-06T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Third Closing Note","agreement_type":"credit_facility","counterparty":"Petrichor Opportunities Fund I LP","effective_date":"2023-12-04","item_codes_triggered":["1.01"],"value_text":"issued $5,000,000 senior secured floating rate convertible note, convertible at $7.89 per share, mat"},"claim":"FENNEC PHARMACEUTICALS INC. entered into Third Closing Note with Petrichor Opportunities Fund I LP valued at issued $5,000,000 senior secured floating rate convertible note, convertible at $7.89 per share, mat (effective 2023-12-04).","evidence_excerpt":"On December 4, 2023, the Company closed a third tranche under the SPA in the amount of $5,000,000 and issued the Investor a Note in the same amount (the “Third Closing Note”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-123728","anchor_url":"https://secwatch.observer/filing/0001104659-23-123728#claim-dfb76f9bba09c1492ac62e623f0f336e796e022c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465923123728/0001104659-23-123728-index.htm"},{"fact_type":"material_agreement","fact_key":"79219a00ea365c400dacd59ab08081998a83d2b6","cik":1211583,"ticker":"FENC","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2023-12-06T23:59:59+00:00","payload":{"action":"entry","agreement_name":"First Amendment to Securities Purchase Agreement","agreement_type":"credit_facility","counterparty":"Petrichor Opportunities Fund I LP","effective_date":"2023-12-04","item_codes_triggered":["1.01"],"value_text":"extended draw period to December 31, 2024 for remaining $15,000,000"},"claim":"FENNEC PHARMACEUTICALS INC. entered into First Amendment to Securities Purchase Agreement with Petrichor Opportunities Fund I LP valued at extended draw period to December 31, 2024 for remaining $15,000,000 (effective 2023-12-04).","evidence_excerpt":"Also on December 4, 2023, the Company entered into a First Amendment to the Securities Purchase Agreement (the “SPA Amendment”) with the Investor, which, among other things, extends the period that the Company may draw the remaining $15,000,000 under the SPA from December 31, 2023 to December 31, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-123728","anchor_url":"https://secwatch.observer/filing/0001104659-23-123728#claim-79219a00ea365c400dacd59ab08081998a83d2b6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465923123728/0001104659-23-123728-index.htm"},{"fact_type":"earnings_release","fact_key":"f0440710fe760a4b81bc26c7130d55eee2213adc","cik":1211583,"ticker":"FENC","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2023-11-07T23:59:59+00:00","payload":{"eps_text":"$0.07 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$1.9 million ($0.07 per share)","period_text":"the third quarter ended September 30, 2023","report_date":"2023-09-30","result_type":"reported_results","revenue_text":"$6.5 million"},"claim":"FENNEC PHARMACEUTICALS INC. reported the third quarter ended September 30, 2023 results: revenue $6.5 million, net income $1.9 million ($0.07 per share), EPS $0.07 per share.","evidence_excerpt":"EXHIBIT 99.1 Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES THIRD QUARTER\n2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ PEDMARK ® Net Product Revenue of $6.5 Million, a 96% Increase Compared to Second Quarter ~ ~ Strong Commercial Uptake Underscoring\nSignificant Unmet Medical Need ~ ~ Received Approval in October 2023 by the Medicines and","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-114905","anchor_url":"https://secwatch.observer/filing/0001104659-23-114905#claim-f0440710fe760a4b81bc26c7130d55eee2213adc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465923114905/0001104659-23-114905-index.htm"}]}